Structural Insights into the Folding Defects of Oncogenic pVHL Lead to Correction of Its Function In Vitro

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Shmueli, Merav D ^a   Schnaider, Lee ^a   Rosenblum, Daniel ^a   Herzog, Gal ^a   Gazit, Ehud ^a   Segal, Daniel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ENHANCED GREEN FLUORESCENT PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VON HIPPEL LINDAU PROTEIN;

ARTICLE; BIOPHYSICS; CARCINOGENICITY; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENE MUTATION; HYDRODYNAMICS; IN VITRO STUDY; MOLECULAR WEIGHT; PREDICTION; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TARGETING; WILD TYPE;

ARGININE; CARCINOMA, RENAL CELL; ESCHERICHIA COLI; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; MODELS, MOLECULAR; MOLECULAR WEIGHT; MUTATION, MISSENSE; OSMOLAR CONCENTRATION; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

BACTERIA (MICROORGANISMS);

EID: 84879262793     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066333     Document Type: Article

References (63)

1. Latif F, Tory K, Gnarra J, Yao M, Duh FM, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320.
2. Maher ER, Kaelin WG Jr, (1997) von Hippel-Lindau disease. Medicine (Baltimore) 76: 381-391.
3. Kim WY, Kaelin WG, (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22: 4991-5004.
4. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, et al. (1994) Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54: 2852-2855.
5. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7: 85-90.
6. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr, (1995) Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 269: 1444-1446.
7. Duan DR, Pause A, Burgess WH, Aso T, Chen DY, et al. (1995) Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269: 1402-1406.
8. Duan DR, Humphrey JS, Chen DY, Weng Y, Sukegawa J, et al. (1995) Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci U S A 92: 6459-6463.
9. Ryan HE, Lo J, Johnson RS, (1998) HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015.
10. Bai C, Sen P, Hofmann K, Ma L, Goebl M, et al. (1996) SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 86: 263-274.
11. Ohh M, Takagi Y, Aso T, Stebbins CE, Pavletich NP, et al. (1999) Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest 104: 1583-1591.
12. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
13. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, et al. (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741.
14. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, et al. (2000) Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 97: 10430-10435.
15. D'Angelo G, Duplan E, Boyer N, Vigne P, Frelin C, (2003) Hypoxia up-regulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1 responses during reoxygenation. J Biol Chem 278: 38183-38187.
16. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, et al. (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427.
17. Miller F, Kentsis A, Osman R, Pan ZQ, (2005) Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex. J Biol Chem 280: 7985-7996.
18. Roe JS, Youn HD, (2006) The positive regulation of p53 by the tumor suppressor VHL. Cell Cycle 5: 2054-2056.
19. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, et al. (2007) pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 28: 15-27.
20. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, et al. (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1: 959-968.
21. Kurban G, Hudon V, Duplan E, Ohh M, Pause A, (2006) Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. Cancer Res 66: 1313-1319.
22. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, et al. (2005) Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8: 155-167.
23. Beroud C, Joly D, Gallou C, Staroz F, Orfanelli MT, et al. (1998) Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res 26: 256-258.
24. Stebbins CE, Kaelin WG Jr, Pavletich NP, (1999) Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284: 455-461.
25. Whaley JM, Naglich J, Gelbert L, Hsia YE, Lamiell JM, et al. (1994) Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 55: 1092-1102.
26. Knauth K, Bex C, Jemth P, Buchberger A, (2006) Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions. Oncogene 25: 370-377.
27. Schoenfeld A, Davidowitz EJ, Burk RD, (1998) A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc Natl Acad Sci U S A 95: 8817-8822.
28. Blankenship C, Naglich JG, Whaley JM, Seizinger B, Kley N, (1999) Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene 18: 1529-1535.
29. Iliopoulos O, Ohh M, Kaelin WG Jr, (1998) pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A 95: 11661-11666.
30. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr, (1995) Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1: 822-826.
31. Sutovsky H, Gazit E, (2004) The von Hippel-Lindau tumor suppressor protein is a molten globule under native conditions: implications for its physiological activities. J Biol Chem 279: 17190-17196.
32. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, et al. (2002) Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science 296: 1886-1889.
33. Chang YC, Oas TG, (2010) Osmolyte-induced folding of an intrinsically disordered protein: folding mechanism in the absence of ligand. Biochemistry 49: 5086-5096.
34. Burley SK, Petsko GA, (1985) Aromatic-aromatic interaction: a mechanism of protein structure stabilization. Science 229: 23-28.
35. Feldman DE, Spiess C, Howard DE, Frydman J, (2003) Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding. Mol Cell 12: 1213-1224.
36. Gryczynski I, Malicka J, Lukomska J, Gryczynski Z, Lakowicz JR, (2004) Surface plasmon-coupled polarized emission of N-acetyl-l-tryptophanamide. Photochem Photobiol 80: 482-485.
37. Lakowicz JR, Maliwal BP, Cherek H, Balter A, (1983) Rotational freedom of tryptophan residues in proteins and peptides. Biochemistry 22: 1741-1752.
38. Martenson RE, (1978) The use of gel filtration to follow conformational changes in proteins. Conformational flexibility of bovine myelin basic protein. J Biol Chem 253: 8887-8893.
39. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54.
40. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472.
41. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468.
42. Waldo GS, Standish BM, Berendzen J, Terwilliger TC, (1999) Rapid protein-folding assay using green fluorescent protein. Nat Biotechnol 17: 691-695.
43. Mayer S, Rudiger S, Ang HC, Joerger AC, Fersht AR, (2007) Correlation of levels of folded recombinant p53 in escherichia coli with thermodynamic stability in vitro. J Mol Biol 372: 268-276.
44. Burg MB, Ferraris JD, (2008) Intracellular organic osmolytes: function and regulation. J Biol Chem 283: 7309-7313.
45. Tsumoto K, Umetsu M, Kumagai I, Ejima D, Philo JS, et al. (2004) Role of arginine in protein refolding, solubilization, and purification. Biotechnol Prog 20: 1301-1308.
46. Feldman DE, Thulasiraman V, Ferreyra RG, Frydman J, (1999) Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol Cell 4: 1051-1061.
47. Dunker AK, Obradovic Z, (2001) The protein trinity-linking function and disorder. Nat Biotechnol 19: 805-806.
48. McClellan AJ, Scott MD, Frydman J, (2005) Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. Cell 121: 739-748.
49. Tompa P, (2002) Intrinsically unstructured proteins. Trends Biochem Sci 27: 527-533.
50. Ohh M, (2006) Ubiquitin pathway in VHL cancer syndrome. Neoplasia 8: 623-629.
51. Arjumand W, Sultana S, (2012) Role of VHL gene mutation in human renal cell carcinoma. Tumour Biol 33: 9-16.
52. Khan SH, Ahmad N, Ahmad F, Kumar R, (2010) Naturally occurring organic osmolytes: from cell physiology to disease prevention. IUBMB Life 62: 891-895.
53. Nagaraj NS, Singh OV, Merchant NB, (2010) Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy. Expert Rev Proteomics 7: 613-623.
54. Chen CH, Terentjev EM, (2009) Aging and metastability of monoglycerides in hydrophobic solutions. Langmuir 25: 6717-6724.
55. Arakawa T, Ejima D, Tsumoto K, Obeyama N, Tanaka Y, et al. (2007) Suppression of protein interactions by arginine: a proposed mechanism of the arginine effects. Biophys Chem 127: 1-8.
56. Li J, Garg M, Shah D, Rajagopalan R, (2010) Solubilization of aromatic and hydrophobic moieties by arginine in aqueous solutions. J Chem Phys 133: 054902.
57. Tsvetkov P, Reuven N, Shaul Y, (2009) The nanny model for IDPs. Nat Chem Biol 5: 778-781.
58. Melville MW, McClellan AJ, Meyer AS, Darveau A, Frydman J, (2003) The Hsp70 and TRiC/CCT chaperone systems cooperate in vivo to assemble the von Hippel-Lindau tumor suppressor complex. Mol Cell Biol 23: 3141-3151.
59. Bourne PE, Westbrook J, Berman HM, (2004) The Protein Data Bank and lessons in data management. Brief Bioinform 5: 23-30.
60. Zhang Y, (2008) I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9: 40.
61. Xu D, Zhang J, Roy A, Zhang Y, (2011) Automated protein structure modeling in CASP9 by I-TASSER pipeline combined with QUARK-based ab initio folding and FG-MD-based structure refinement. Proteins 79Suppl 10: 147-160.
62. Tanford C, (1968) Protein denaturation. Adv Protein Chem 23: 121-282.
63. Pace CN, (1990) Measuring and increasing protein stability. Trends Biotechnol 8: 93-98.